Eli Lilly and Company (LLY)
Lilly CEO: U.K. has gone from biopharma leader to laggard
Lilly CEO Dave Ricks explains why pricing dynamics in the U.K. make it a very unattractive place for Lilly to invest.
Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
Eli Lilly on Tuesday said it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, to boost production capacity for targeted cancer drugs and other treatments. The plant is the company's first of four planned U.S. manufacturing sites, which will begin making medicines within five years.
Oxford Industries says new Lilly Pulitzer offerings are winning over shoppers, but its Tommy Bahama line is lagging
Resort-style clothing maker Oxford Industries Inc. on Wednesday offered up mixed second-quarter results and third-quarter expectations, and said that while new Lilly Pulitzer offerings were attracting shoppers, its Tommy Bahama line wasn't.
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
Eli Lilly launches platform for AI-enabled drug discovery
Drugmaker Eli Lilly said on Tuesday it is launching an artificial intelligence and machine learning platform that provides biotech companies access to drug discovery models trained on years of Lilly's research data.
Novo Nordisk Vs Eli Lilly: Novo A Clear Winner
Novo Nordisk stands out as the best pharma stock, outperforming Eli Lilly in key areas. Novo's higher profitability, stronger cash flow, and much lower valuation make it a more attractive investment than Lilly. Novo's discount could become a premium, as investors seek to diversify away from US stocks.
Eli Lilly's Stock Fall Is An Opportunity
I am bullish on Eli Lilly, despite recent underperformance and Orforglipron's clinical results falling short of high expectations. Eli Lilly's robust R&D, strong pipeline, and leadership in diabetes, obesity, and oncology underpin its long-term growth prospects. Recent financial results exceeded expectations, with raised guidance and continued market share gains in weight loss therapies, supporting valuation upside.
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
Novo's Wegovy Beats Lilly's Zepbound for Heart Health, Study Finds. What It Means for Stocks.
The study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to semaglutide.
Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study
Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.
Eli Lilly advances weight loss pill towards regulatory submissions after successful trial
Eli Lilly and Co (NYSE:LLY) shares moved higher Tuesday after the company reported positive late-stage trial results for its experimental oral obesity and diabetes drug, orforglipron. The Phase 3 study, known as ATTAIN-2, tested orforglipron in adults with obesity or overweight who also have Type 2 diabetes.
